Praxis Precision Medicine Surges on FDA Breakthrough Recognition

17 days ago

Alex Sinova

"So can always count on biotech companies to show some outsized moves and one of them is Praxis Precision Medicine. That is ticker PRAX. It soared as much as 18% today to breach the highest intraday level since 2021. This is a biotech company that received a breakthrough therapy designation by the FDA for treatment of patients with essential tremor. Piper Sandler analysts say that they notched another major win with this development. They believe that Praxis is positioned for a monumental 2026."

The segment underscores a significant surge in PRAX, driven by its breakthrough therapy designation and strong analyst support, suggesting considerable upside potential into 2026. The achievement marks a critical catalyst for the company in the biotech space.

Related Stocks